Salem A, et al. - Researchers sought to determine the features and results in patients with stage I to II small cell lung cancer (SCLC) treated with chemoradiotherapy via this secondary analysis of the Concurrent Once-Daily vs Twice-Daily Radiotherapy Trial (CONVERT), among 509 patients. This is identified to be the first study reporting on stage I to II SCLC within a randomized clinical trial in the era of modern radiotherapy. Outcomes revealed longer overall survival among patients with stage I to II small cell lung cancer vs those with stage III disease, with satisfactory adverse effects following chemoradiotherapy and prophylactic cranial irradiation. These findings may help practitioners to guide their patients in clinical decisions.